Ensign Peak Advisors’s Avidity Biosciences RNAM Stock Holding History

Ensign Peak Advisors’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-122,393	Closed	-$8.83M	–	1731
2025 Q4	$8.83M	Sell	122,393 -458,464	-79%	-$29.6M	0.02%	428
2025 Q3	$25.3M	Buy	580,857 +50,043	+9%	+$2.02M	0.04%	279
2025 Q2	$15.1M	Buy	530,814 +200,836	+61%	+$5.99M	0.03%	376
2025 Q1	$9.74M	Buy	329,978 +302,028	+1,081%	+$9.41M	0.02%	471
2024 Q4	$813K	Buy	27,950 +5,550	+25%	+$232K	﹤0.01%	1446
2024 Q3	$1.03M	Hold	22,400	–	–	﹤0.01%	1306
2024 Q2	$915K	Hold	22,400	–	–	﹤0.01%	1338
2024 Q1	$572K	Buy	+22,400	New	+$351K	﹤0.01%	1590
2022 Q4	–	Sell	-11,480	Closed	-$187K	–	2139
2022 Q3	$187K	Buy	11,480 +660	+6%	+$12.6K	﹤0.01%	1903
2022 Q2	$157K	Hold	10,820	–	–	﹤0.01%	1868
2022 Q1	$200K	Hold	10,820	–	–	﹤0.01%	1877
2021 Q4	$257K	Buy	+10,820	New	+$258K	﹤0.01%	1866

Other funds holding RNAM

Corsicana & Co Corsicana, Texas $158M AUM

Ensign Peak Advisors's RNAM Position: Q1 2026 in Review

Ensign Peak Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 122,393 shares — an estimated $8.83M sold.

Ensign Peak Advisors first reported a position in RNAM in Q4 2021 and held it in 12 quarters. The position peaked at $25.3M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

Ensign Peak Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
Ensign Peak Advisors sold 122,393 Avidity Biosciences shares in Q1 2026, an estimated $8.83M.
Ensign Peak Advisors first reported a position in Avidity Biosciences in Q4 2021 and held it in 12 quarters.
Ensign Peak Advisors's Avidity Biosciences position peaked at $25.3M in Q3 2025.
1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.